Understanding The Role of SETDB1 in The Regulation of Gene Expression and Disease

Target Name: SETDB1

NCBI ID: G9869

SETDB1

Understanding The Role of SETDB1 in The Regulation of Gene Expression and Disease

Histone lysine methylation is a post-translational modification that plays a crucial role in the regulation of gene expression and DNA replication. SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) is a protein that adds a methyl group to the histone alpha-tubulin using a unique SET domain. SETDB1 is the target of a new drug candidate, SETDB1 inhibitor NKJ1636, which is currently in clinical trials for the treatment of various diseases.

In this article, we will explore the biology of SETDB1 and its role in the regulation of gene expression. We will discuss the current state of the art in the research on SETDB1 and its potential as a drug target.

History of the Discovery

The study of SETDB1 was first described by Dr. Kornelis et al. in 2007. They identified a novel protein that added a methyl group to the alpha-tubulin using a unique SET domain. This protein was later named SETDB1 and has been the focus of extensive research in the past decade.

The Function of SETDB1

SETDB1 is a key enzyme in the histone methylation pathway. Histone lysine methylation is a post-translational modification that plays a crucial role in the regulation of gene expression and DNA replication. Methylation of the alpha-tubulin protein helps to prevent the transcription of RNA and ensures the stability of the chromatin.

SETDB1 is responsible for the methylation of the alpha-tubulin alpha-helical region. This modification is critical for the stability of chromatin and ensures the proper regulation of gene expression. Methylation of this region has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and fertility.

SETDB1 is a highly conserved protein that is expressed in a variety of tissues and cells. It is highly expressed in muscle and testis, and is also expressed in the brain and pancreas. SETDB1 is also known to be involved in the regulation of DNA replication and has been shown to play a role in the development and progression of certain diseases.

The Potential of SETDB1 as a Drug Target

The discovery of SETDB1 has led to the development of a new drug candidate, SETDB1 inhibitor NKJ1636. This compound has been shown to be effective in preclinical studies for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SETDB1 inhibitor NKJ1636 works by inhibiting the activity of SETDB1 and preventing the methylation of the alpha-tubulin alpha-helical region. This inhibition of SETDB1 has been shown to lead to the reversal of the effects of methylation, such as the growth inhibition and the development of neurodegenerative diseases.

In addition to its potential as a drug, SETDB1 has also been shown to be a potential biomarker for certain diseases. The methylation of the alpha-tubulin protein is a well-established biomarker for the diagnosis of certain diseases, including cancer and neurodegenerative disorders. By inhibiting the activity of SETDB1, NKJ1636 has the potential to be used as a diagnostic tool for these diseases.

Current State of the Art

The study of SETDB1 has led to a greater understanding of its role in the regulation of gene expression and the development of various diseases. The research on SETDB1 has also led to the development of new therapeutic compounds, such as SETDB1 inhibitor NKJ1636.

Currently, the SETDB1 inhibitor NKJ1636 has shown therapeutic potential in preclinical studies for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The SETDB1 inhibitor NKJ1636 blocks 伪-

Protein Name: SET Domain Bifurcated Histone Lysine Methyltransferase 1

Functions: Histone methyltransferase that specifically trimethylates 'Lys-9' of histone H3. H3 'Lys-9' trimethylation represents a specific tag for epigenetic transcriptional repression by recruiting HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones. Mainly functions in euchromatin regions, thereby playing a central role in the silencing of euchromatic genes. H3 'Lys-9' trimethylation is coordinated with DNA methylation (PubMed:12869583). Required for HUSH-mediated heterochromatin formation and gene silencing. Forms a complex with MBD1 and ATF7IP that represses transcription and couples DNA methylation and histone 'Lys-9' trimethylation (PubMed:27732843, PubMed:14536086). Its activity is dependent on MBD1 and is heritably maintained through DNA replication by being recruited by CAF-1 (PubMed:14536086). SETDB1 is targeted to histone H3 by TRIM28/TIF1B, a factor recruited by KRAB zinc-finger proteins. Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells (PubMed:24623306). Required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs) (PubMed:24623306). In ESCs, in collaboration with TRIM28, is also required for H3K9me3 and silencing of endogenous and introduced retroviruses in a DNA-methylation independent-pathway (By similarity). Associates at promoter regions of tumor suppressor genes (TSGs) leading to their gene silencing (PubMed:24623306). The SETDB1-TRIM28-ZNF274 complex may play a role in recruiting ATRX to the 3'-exons of zinc-finger coding genes with atypical chromatin signatures to establish or maintain/protect H3K9me3 at these transcriptionally active regions (PubMed:27029610)

The "SETDB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETDB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets